Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

Peter J O’Brien1, Rajeev Ramanathan2, Jonathan M Yingling1, Jose Baselga3, Mace L Rothenberg4, Michael Carducci5, Thomas Daly1, Dorothy Adcock2, Michael Lahn11Eli Lilly and Company Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA; 2Esoterix Coagulation, Aurora, CO,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Peter J O’Brien, Rajeev Ramanathan, Jonathan M Yingling, Jose Baselga, Mace L Rothenberg, et al
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/eb6a465b749d4abc800f350f26a9a6fa
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:eb6a465b749d4abc800f350f26a9a6fa
record_format dspace
spelling oai:doaj.org-article:eb6a465b749d4abc800f350f26a9a6fa2021-12-02T07:23:16ZAnalysis and variability of TGFβ measurements in cancer patients with skeletal metastases1177-54751177-5491https://doaj.org/article/eb6a465b749d4abc800f350f26a9a6fa2008-09-01T00:00:00Zhttp://www.dovepress.com/analysis-and-variability-of-tgfbeta-measurements-in-cancer-patients-wi-a2305https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Peter J O’Brien1, Rajeev Ramanathan2, Jonathan M Yingling1, Jose Baselga3, Mace L Rothenberg4, Michael Carducci5, Thomas Daly1, Dorothy Adcock2, Michael Lahn11Eli Lilly and Company Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA; 2Esoterix Coagulation, Aurora, CO, USA; 3Vall d’Hebron University Hospital, Barcelona, Spain; 4Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USAAbstract: Transforming growth factor beta (TGFβ) plays an important role in cancer, but accurate measurement of circulating TGFβ is complicated by the high TGFβ content of platelets which can release TGFβ ex vivo. We evaluated the use of citrate-theophylline-adenosine-dipyridamole (CTAD) tubes to reduce preanalytical variation in TGFβ measurements caused by ex vivo platelet activation. CTAD substantially reduced ex vivo platelet activation relative to traditional plasma collections in normal donors, which correlated with a decrease in measured TGFβ levels. We show that TGFβ levels are elevated in the majority of cancer patients with skeletal metastases, and that within-patient variability of these levels is relatively low over several weeks. Patients with elevated TGFβ could be subdivided into groups with or without evidence of platelet contribution to measured TGFβ levels. The use of CTAD tubes allows a better determination of a patient’s TGFβ status, and may improve classification of patients with oncologic disease.Keywords: TGFβ, cancer, biomarker, CTAD Peter J O’BrienRajeev RamanathanJonathan M YinglingJose BaselgaMace L Rothenberget alDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 563-569 (2008)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Peter J O’Brien
Rajeev Ramanathan
Jonathan M Yingling
Jose Baselga
Mace L Rothenberg
et al
Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases
description Peter J O’Brien1, Rajeev Ramanathan2, Jonathan M Yingling1, Jose Baselga3, Mace L Rothenberg4, Michael Carducci5, Thomas Daly1, Dorothy Adcock2, Michael Lahn11Eli Lilly and Company Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA; 2Esoterix Coagulation, Aurora, CO, USA; 3Vall d’Hebron University Hospital, Barcelona, Spain; 4Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA; 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USAAbstract: Transforming growth factor beta (TGFβ) plays an important role in cancer, but accurate measurement of circulating TGFβ is complicated by the high TGFβ content of platelets which can release TGFβ ex vivo. We evaluated the use of citrate-theophylline-adenosine-dipyridamole (CTAD) tubes to reduce preanalytical variation in TGFβ measurements caused by ex vivo platelet activation. CTAD substantially reduced ex vivo platelet activation relative to traditional plasma collections in normal donors, which correlated with a decrease in measured TGFβ levels. We show that TGFβ levels are elevated in the majority of cancer patients with skeletal metastases, and that within-patient variability of these levels is relatively low over several weeks. Patients with elevated TGFβ could be subdivided into groups with or without evidence of platelet contribution to measured TGFβ levels. The use of CTAD tubes allows a better determination of a patient’s TGFβ status, and may improve classification of patients with oncologic disease.Keywords: TGFβ, cancer, biomarker, CTAD
format article
author Peter J O’Brien
Rajeev Ramanathan
Jonathan M Yingling
Jose Baselga
Mace L Rothenberg
et al
author_facet Peter J O’Brien
Rajeev Ramanathan
Jonathan M Yingling
Jose Baselga
Mace L Rothenberg
et al
author_sort Peter J O’Brien
title Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases
title_short Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases
title_full Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases
title_fullStr Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases
title_full_unstemmed Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases
title_sort analysis and variability of tgfβ measurements in cancer patients with skeletal metastases
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/eb6a465b749d4abc800f350f26a9a6fa
work_keys_str_mv AT peterjoamprsquobrien analysisandvariabilityoftgfampbetameasurementsincancerpatientswithskeletalmetastases
AT rajeevramanathan analysisandvariabilityoftgfampbetameasurementsincancerpatientswithskeletalmetastases
AT jonathanmyingling analysisandvariabilityoftgfampbetameasurementsincancerpatientswithskeletalmetastases
AT josebaselga analysisandvariabilityoftgfampbetameasurementsincancerpatientswithskeletalmetastases
AT macelrothenberg analysisandvariabilityoftgfampbetameasurementsincancerpatientswithskeletalmetastases
AT etal analysisandvariabilityoftgfampbetameasurementsincancerpatientswithskeletalmetastases
_version_ 1718399490151415808

Ejemplares similares